American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)

Sponsor
University of New Mexico (Other)
Overall Status
Recruiting
CT.gov ID
NCT04185844
Collaborator
(none)
500
3
46
166.7
3.6

Study Details

Study Description

Brief Summary

Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - "CRIC 2018" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Investigators will conduct a longitudinal study of a CKD cohort of Southwest AIs to identify unique risk factors for CKD and CVD progression and compare CKD and CVD event rates and risk factors between AI and the populations represented in CRIC. Investigators will establish a specimen bank to support future ancillary studies designed to identify and examine biomarkers associated with the progression of CKD in AIs.

    At the Clinic Visit the following will occur:
    • weight is measured

    • blood pressure and heart rate are recorded

    • information about medical history and medication used recently

    • blood draw (about ½ cup) for the following tests: CBC (Complete Blood Count), tests of metabolism, and several other heart and kidney tests

    • blood pressure in the leg and arm calculated as the Ankle Brachial Index (ABI)

    • urine sample collection for kidney function testing

    • complete questionnaires about quality of life, diet, mood, thought processes and physical activity.

    This visit takes about 1 to 2 hours. Participants will be contacted by telephone six months after the Baseline Visit to ask about recent medical events and medications.

    Participants will be asked to return to the center for annual visits during which many but not all of the procedures described above will be conducted.

    Additionally, participants will be asked to participate in one of two substudies using remote data collection techniques to identify trajectories of kidney function and cardiovascular risk sub-phenotypes

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)
    Actual Study Start Date :
    Aug 31, 2020
    Anticipated Primary Completion Date :
    Apr 30, 2024
    Anticipated Study Completion Date :
    Jun 30, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Slope of the GFR [5 years]

      Primary outcomes regarding Cardio vascular disease will focus on clinical events indicative of ischemic heart disease, CHF, stroke, and peripheral vascular disease supplemented by radiographic evidence of progressive CVD.

    Secondary Outcome Measures

    1. Onset of End Stage Renal Disease [5 years]

      The measure is reflected in decline of GFR levels

    2. Significant loss of renal function [5 years]

      The measure is reflected in decline of GFR levels

    3. Composite clinical outcome defined by the occurrence of either 50% decline, or 25 l/min/1.73 m2 decline in GFR from baseline, or onset of ESRD [5 years]

      The composite clinical outcome includes onset of End Stage Renal Disease, Significant loss of renal function or changes in proteinuria over time from baseline

    4. Slope of change in proteinuria over time [5 years]

      The changes in the levels of proteinuria overtime

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Glomerular Filtration Rate (GFR): eGFR of =>61<80 and microalbuminuria > 30 or eGRF of =<60 (no microalbuminuria required).
    Exclusion Criteria:
    1. Unable or unwilling to provide informed consent

    2. life expectancy <3 years;

    3. institutionalized subjects;

    4. End stage renal disease or renal transplant;

    5. renal cancer;

    6. myeloma;

    7. immunosuppression;

    8. Polycystic kidney disease;

    9. participation in any clinical trial,

    10. current pregnancy

    11. current incarceration.

    12. Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NIDDK-Phoenix Epidemiology and Clinical Research Phoenix Arizona United States 85016
    2 First Nations Community Health Source Albuquerque New Mexico United States 87108
    3 Zuni Health Initiative Center Black Rock New Mexico United States 87327

    Sponsors and Collaborators

    • University of New Mexico

    Investigators

    • Principal Investigator: Vallabh Shah, University of New Mexico

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    University of New Mexico
    ClinicalTrials.gov Identifier:
    NCT04185844
    Other Study ID Numbers:
    • 19-159
    First Posted:
    Dec 4, 2019
    Last Update Posted:
    May 25, 2022
    Last Verified:
    May 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 25, 2022